J Mol Cell Biol:徐鹰等发现低氧可以驱动癌症生长

2012-07-03 上海生命科学研究院 上海生命科学研究院

Journal of Molecular Cell Biology(《分子细胞生物学报》)2012年第3期“复杂疾病的系统生物学研究”专辑中发表了一篇美国佐治亚大学生物化学与分子生物学系徐鹰教授关于“Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive

Journal of Molecular Cell Biology(《分子细胞生物学报》)2012年第3期“复杂疾病的系统生物学研究”专辑中发表了一篇美国佐治亚大学生物化学与分子生物学系徐鹰教授关于“Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster” 的论文,报道了细胞内低氧引起能量效率与控制细胞增殖的关系的失调,从而促进肿瘤的快速生长。这一假设与传统认为的“基因突变导致肿瘤生长”观点有着很大的区别。此文在线出版后,立即受到包括ScienceDaily在内的国际媒体广泛关注。

过去的研究将细胞内低氧水平看作癌症发展的促进因素之一,但并不是肿瘤生长的驱动因素。徐教授说,随机的基因突变单独无法解释全球癌症的高发病率。他又说,将数学和计算机知识应用于生物学而形成的生物信息学使研究人员可以从一种新的角度看待癌症。基因突变可能使癌细胞在竞争中优于健康细胞,但这样的话新生癌细胞生长的模式就不需要癌变前兆的出现,如原癌基因突增等常见的不良变化。“癌症治疗药物力求达到根源——在分子水平上——一个特定的突变,但往往不能根治,”徐教授说:“所以我们想基因突变可能并不是癌症的主要驱动因素。”的确,徐教授的分析发现,长期的细胞内缺氧可能是癌生长的一个关键驱动因素。

目前大多数的癌症研究希望通过药物对抗与某种特定癌症相关的基因突变,进而达到治疗癌症的目的。徐教授课题组从Stanford Microarray Database数据库下载了7种癌症(乳腺癌、肾癌、肝癌、肺癌、卵巢癌、胰腺癌及胃癌)的相关数据,通过一款软件程序分析这7种癌症中异常的基因表达模式。他们以基因HIF1A作为一个细胞氧含量的标记物,所有被实验的7种癌细胞中,HIF1A水平都有显著的升高,这表明这些癌细胞中氧含量显著的降低。

细胞内氧含量降低,导致氧化磷酸化反应的中断,而氧化磷酸化反应是细胞将食物转化为能量的一种高效途径。随着氧含量的降低,细胞切换到糖酵解途径生产能量单位,即ATP,这是一种效率非常低的能量获取方式,所以为了存活癌细胞必须努力得到更多的食物,尤其是葡萄糖。当氧含量水平下降到极限时,血管新生——即生成新血管的过程——启动了。新生血管提供新鲜的氧气,提高细胞内和肿瘤的氧含量水平,并延缓癌细胞的生长,但这都是暂时的。

“得到更多的食物后,癌细胞就会生长;这就会导致整个肿瘤实体增长而更加缺氧。反过来,能量转换效率将更加低下,从而使细胞更加饥饿,促使细胞从血液循环中获得更多的食物,形成一个恶性循环。这或许是肿瘤形成的一个关键驱动因素,”徐说。这个全新的癌细胞生长模式可能用于解释为什么很多肿瘤很快(3-6个月以内)产生耐药性。他强调了未来非常有必要通过大量的癌症实验研究来论证这一新模式。如果这一模式得以成立,研究人员的首要任务是探索防止细胞内低氧的办法,从而使肿瘤治疗的手段发生巨大改变。

doi:10.1093/jmcb/mjs017
PMC:
PMID:

Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster

Juan Cui1,†, Xizeng Mao1,†, Victor Olman1, P. J. Hastings2 and Ying Xu1,3,*

The question we address here is what drives cancer to grow in an accelerated fashion as it evolves. Various proposals have been made regarding the possible drivers of cancer growth such as driver mutations and autonomous growth signaling. While these are clearly relevant, they rely too much on specific types of genomic mutations or molecular abnormalities by chance across different cancer types, which makes the probability for cancer to occur/progress significantly lower than what we have witnessed about the current cancer occurrence rates worldwide, hence making them less probable to be the ultimate drivers of cancer growth (Loeb, 1998). We present here a model for the (accelerated) growth of a cancer based on the discovered gene-expression patterns derived from genome-scale transcriptomic data of seven solid carcinoma types, namely breast, kidney, liver, lung, ovary, pancreatic, and stomach cancers. Our data analysis clearly indicates that as a cancer advances, (i) its percentage of cells in the G0 phase of the cell cycle tends to become increasingly lower, indicating accelerated cell proliferation; (ii) when the hypoxia level goes up, the activity level of oxidative phosphorylation as the main energy (ATP) producer goes down and that of glycolysis goes up, which triggers cancer cells to accelerate the uptake of glucose from the blood circulation to make up for the lost efficiency in energy production, needed for them to stay viable; (iii) this switch in energy metabolisms leads to accelerated cell proliferation and further increased hypoxia, forming a vicious cycle of (accelerated) growth of cancer; (iv) this cycle breaks down when the new angiogenesis takes place triggered by the high hypoxia level, which decreases the hypoxia level and switches back to oxidative phosphorylation as the main energy producer and continues until the cells become too hypoxic again; and (v) the cellular hypoxia …

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766794, encodeId=72391e6679474, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Apr 02 10:08:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916906, encodeId=d6491916906cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Apr 30 05:08:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868544, encodeId=3d921868544c6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 01:08:00 CST 2012, time=2012-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958776, encodeId=e6391958e768d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 28 13:08:00 CST 2013, time=2013-04-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766794, encodeId=72391e6679474, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Apr 02 10:08:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916906, encodeId=d6491916906cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Apr 30 05:08:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868544, encodeId=3d921868544c6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 01:08:00 CST 2012, time=2012-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958776, encodeId=e6391958e768d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 28 13:08:00 CST 2013, time=2013-04-28, status=1, ipAttribution=)]
    2013-04-30 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766794, encodeId=72391e6679474, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Apr 02 10:08:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916906, encodeId=d6491916906cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Apr 30 05:08:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868544, encodeId=3d921868544c6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 01:08:00 CST 2012, time=2012-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958776, encodeId=e6391958e768d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 28 13:08:00 CST 2013, time=2013-04-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766794, encodeId=72391e6679474, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Apr 02 10:08:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916906, encodeId=d6491916906cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Apr 30 05:08:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868544, encodeId=3d921868544c6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 01:08:00 CST 2012, time=2012-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958776, encodeId=e6391958e768d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 28 13:08:00 CST 2013, time=2013-04-28, status=1, ipAttribution=)]
    2013-04-28 维他命

相关资讯

Int J Oncol:阻断缺氧调控的TMPRSS4治疗肿瘤

早期研究证实TMPRSS4的过度表达与胰腺癌、大肠癌和甲状腺癌等类型癌症的发生发展有关。TMPRSS4是一种细胞表面跨膜丝氨酸蛋白酶,这一蛋白的表达对肿瘤细胞的迁移和转移有作用。 过去,有几项研究探讨了TMPRSS4基因表达水平以及蛋白产物。最近刊登在Int J Oncol杂志上的一则研究中,研究人员用定量RT-PCR和蛋白质染色来评估原发性非小细胞肺癌(NSCLC)组织和肺肿瘤细胞株中TMPR

J Immunol:MicroRNA-494对免疫细胞的募集至关重要

髓系来源抑制细胞(myeloid-derived suppressor cells,MDSCs)是未分化成熟的、异质性的、具有免疫抑制功能的髓系细胞群体。MDSCs能有效抑制抗肿瘤免疫反应,有利于肿瘤的血管生成和转移的肿瘤微环境。 到目前为止,肿瘤调节MDSCs的聚集功能分子网络在很大程度上是未知的。近日,Liu Y, 等研究人员在J Immunol杂志上发表论文称microRNA-494的表达

Clin J Am Soc Nephrol:抗GBM线性抗原表位抗体与患者肾损伤相关

  北京大学第一医院赵明辉等研究发现,在抗肾小球基底膜(GBM)病患者中,可以检测到抗 肾小球基底膜Ⅳ型胶原α3链非胶原区1[α3(Ⅳ)NC1]上线性表位的抗体,且该抗体与患者的肾损伤相关。该论文发表于《美国肾脏病学会临床杂志》(Clin J Am Soc Nephrol. 2012 Jun;7(6):926-33)。     研究人员共纳入68例抗GBM病患者,并合成了人α3(Ⅳ)

Asian J Androl:VEGFA的非促血管生成作用

在一些恶性肿瘤类型中,缺氧和转化生长因子-β1(转化生长因子-β1)能增加血管内皮生长因子(VEGFA)的表达。这种低氧和TGF-β1可能对晚期前列腺癌患者肿瘤的进展和转移具有关键影响。 近日,刊登在Asian Journal of Andrology杂志上的一则研究中,研究人员发现TGF-β1能诱导正常细胞株(HPV7和RWPE1)和前列腺癌的细胞株(DU145和PC3)分泌VEGFA(165

J Immunol:血小板减少后抑制肿瘤转移

血小板与肿瘤细胞相互作用形成癌栓是肿瘤细胞发生转移和远端定位的关键血小板可以在以下方面利于肿瘤的血行转移:1)与肿瘤细胞形成癌栓保护层而与免疫防御系统隔离,有利于肿瘤细胞在循环运输过程的存活;2)使肿瘤细胞成功地抵御了血流的高剪切力的损伤而存活在血液中,从而保护肿瘤细胞免受机体防御机制的清除。 在小鼠体内血小板数目的减少能抑制肿瘤的生长,尤其对抑制肿瘤转移来说非常有效,而NK细胞的缺失却会逆转血

Int J Oncol:川芎嗪靶向COX-2抑制肿瘤转移

环氧化酶(cyclooxygenase,COX)是参与花生四烯酸的环氧酶代谢途径中的限速酶,可催化花生四烯酸转化为前列腺素(prostaglandins,PGs)。近年来研究显示,COX-2在一些肿瘤中存在过度表达现象,提示COX-2可能与肿瘤的发生发展密切相关。 环氧合酶(COX)-2在肺癌中起着重要作用,是肺癌侵袭和转移的关键因素。传统中药川芎有效成分川芎嗪(TMP),历来用于治疗神经、血管